BC3402 + durvalumab

BC3402 + durvalumab is an experimental **combination therapy** for **advanced hepatocellular carcinoma (HCC)**, consisting of the anti-TIM-3 monoclonal antibody **BC3402** and the anti-PD-L1 monoclonal antibody **durvalumab** (brand name: Imfinzi)[1][3][9]. - **BC3402** is a humanized IgG4 monoclonal antibody that targets TIM-3, an immune checkpoint receptor highly expressed in HCC and other tumors resistant to PD-1/PD-L1 inhibitors[1][3][5]. It blocks binding of ligands such as CEACAM1, phosphatidylserine (PtdSer), and galectin-9 (Gal-9), thereby reducing Treg inhibitory effects and restoring T-cell IL-2 production[1][3]. - **Durvalumab** is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 and its receptor, allowing T cells to recognize and kill cancer cells[2][4][6]. The combination aims to **synergistically enhance anti-tumor immune responses** by simultaneous inhibition of the TIM-3 and PD-L1 checkpoints[1][3][9]. BC3402 is developed by **BioCity Biopharma**, and durvalumab by **AstraZeneca**; both companies are collaborating on development in China[1][3][9]. Phase Ib/II trials are underway for advanced HCC[1][3][9].

Other names

BC3402BC-3402BC 3402durvalumab